IgG glycosylation in autoimmune diseases
Immunoglobulin G (IgG) is the most abundant glycoprotein in human serum. All IgG subclasses have a single-conserved N-linked glycosylation site at Asn297 of the heavy chain and 10–30% of IgGs are N-glycosylated also in a Fab region. N-glycans of Fc are sialylated and fucosylated biantennary complex-...
Saved in:
Published in: | Postȩpy higieny i medycyny doświadczalnej Vol. 72; pp. 975 - 990 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
12-11-2018
|
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Immunoglobulin G (IgG) is the most abundant glycoprotein in human serum. All IgG subclasses have a single-conserved N-linked glycosylation site at Asn297 of the heavy chain and 10–30% of IgGs are N-glycosylated also in a Fab region. N-glycans of Fc are sialylated and fucosylated biantennary complex-type structures. Glycosylation plays a key role in antibody function, and IgG N-glycans are essential for the proper activity of the immune system. Fc glycans are
important for IgG effector functions, whereas Fab oligosaccharides modulate antigen binding.
Glycosylation changes of IgG are associated with the development of various human diseases,
including autoimmune states. The modification of one sugar moiety in N-glycan structure may
result in the stimulation or suppression of immune response. The lack of core fucose leads to
the enhancement of pro-inflammatory activity, whereas an increase of sialylation determines
immunosuppressive properties of IgG. The contribution of IgG Fc glycosylation changes has
been demonstrated in the pathogenesis of rheumatoid arthritis, lupus erythematosus and
Crohn’s disease. A decrease in IgG galactosylation and sialylation, found in these diseases,
activates effector cells and triggers inflammatory reactions. A detailed analysis of changes in
IgG glycosylation and their effects on the development of autoimmune diseases is important
in the treatment of these diseases. IgGs with modified α2,6-sialylation are used as therapeutic
antibodies with anti-inflammatory properties. Numerous studies on IgG glycosylation have
provided evidence of the role of this post-translational modification in the proper functioning
of antibodies and the importance of changes in the structure of IgG glycans, mainly incomplete
galactosylation and desialylation, in the pathogenesis of many diseases. The continuation
of these studies may contribute to explaining the mechanisms of autoimmunity that is still
poorly understood. |
---|---|
ISSN: | 0032-5449 1732-2693 |
DOI: | 10.5604/01.3001.0012.7351 |